Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Over the course of 72 weeks, Lilly tested Zepbound and Wegovy on a population of adults with obesity or patients with "at least one weight-related medical problem and without diabetes." ...

beating the performance of the Medical sector with its loss of 3.78% and the S&P 500's gain of 0.22%. The investment community will be closely monitoring the performance of Eli Lilly in its ...

outpacing the Medical sector's loss of 5.64% and lagging the S&P 500's loss of 0.36% in that time. Market participants will be closely following the financial results of Eli Lilly in its upcoming ...